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The value of fenestrated-branched stent-grafts (FBSG) in the
management of complex aortic aneurysms has been clearly
demonstrated from data derived from several centers of excel-
lence. Reducedmorbidity andmortality aswell as shorter length
of hospital stay has been demonstrated to be associated with
FBSG compared to traditional open surgery for patients with
complex aortic aneurysms. FBGS have an even greater beneﬁt in
patients considered to be at high-risk for open repair.1e3
Fenestrated-branched technology was ﬁrst introduced in
1996 with larger series reported in 2001.4e6 Recent reports
have proven FBSG to be safe, effective, and durable with
excellent long-term results. Reinterventions that were per-
formed were mostly for stenoses of branch stents and type 1
and 3 endoleaks.7,8 Cook Medical Inc (Bloomington, IN) has
been a leading manufacturer in this area for several years
with the company reportingmore than 4000 implantations of
FBSG worldwide and recently acquiring FDA approval for its
pararenal device in the United States and CE approval for its
thoracoabdominal device (T-fenestrated) in Europe. Recently,
however, fenestrated-branched technology has rapidly
evolved and become more widespread with 2 more FBSG
devices under investigation or marketed outside of the
U.S.9,10 and FBSG for thoracoabdominal and aortic arch
aneurysms being approved as investigational devices.11
Despite these recent advancements, this technology
which was introduced more than 15 years ago and which
has been used to treat more than 4000 patients worldwide,
not counting the countless patients treated with surgeon-
modiﬁed FBSG or FBSG from other companies, continues to
be restricted to only a few centers of excellence.
The intent of this paper is to argue in favor of a wider
distribution of FBSG to vascular centers and to demonstrate
how any effort to restrict this kind of technology would only
compromise patient care.WHAT KIND OF CASES, SURGEONS AND CENTERS ARE WE
DISCUSSING HERE?
Complexity of FEVAR cases
Fenestrated Endovascular Aneurysm Repair (FEVAR) is
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lenges. Juxta- and pararenal aneurysms, thoracoabdominal
aortic aneurysms (TAAA), and aortic arch aneurysms
although all treated with FEVAR, are different procedures,
each associated with different procedural risks and varying
degrees of difﬁculty and complexity.
The mortality rate for open surgical repair of juxtarenal
aneurysms in contemporary series ranges between 2.5 and
2.9%,12,13 while contemporary results for open repair of
type IV TAAA demonstrate a two-fold higher mortality rate
of 4.4e5.9%.14,15
Similarly, FEVAR with repair extending above the level of
the SMA or the celiac artery (Suprarenal AAA or TAAA) is
associated with a higher rate of severe complications such
as spinal cord ischemia, stroke and renal insufﬁciency than
FEVAR repair that stays below the SMA (Juxtarenal AAA), as
a result of longer procedure times, more catheter and wire
manipulation, increased coverage of the aorta, and the
more challenging alignment of all fenestrations to the
visceral branches. FEVAR for juxtarenal aneurysms has
a mortality of 0e4%,1,16 while the mortality of FEVAR for
TAAA is reported at 6e10%1,17,18 with a risk of permanent
spinal cord ischemia and permanent renal ischemia of 2%.1
Thus, it is obvious that the challenges of a TAAA repair
with FEVAR are greater than that of pararenal aneurysm
repair, and it is the experience of the surgeon and the
center that predominantly determines the outcomes of
FEVAR in these cases.Selection of FEVAR centers and surgeons
Young et al.19 demonstrated in their meta-analysis that
a caseload of 13 AAA repairs/year resulted in signiﬁcantly
better survival for elective aortic aneurysm repair. Evidence
suggests that it is mostly the individual surgeon’s volume
rather than the institution’s volume that improve outcome,
although these interact to improve outcome.19 But even if
one extrapolates data from such studies to use for FEVAR, it
is obvious that a threshold of 13 or 15 or even 20 complex
aneurysms is a number that can be achieved in a signiﬁcant
number of vascular institutions and by a signiﬁcant number
of surgeons and is not limited to just a few centers around
the world.
Excellent endovascular skills and vast experience with
endovascular aortic aneurysm repair are not qualities
conﬁned only to surgeons at the world’s largest aortic
centers. An experienced surgeon, skilled to perform this
procedure may well be found outside large centers.
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a large center does not guarantee that person performing
the procedure is adequately trained to perform it.
Rather, it is more important to focus on what speciﬁc
credentials and competencies the endovascular surgeons
must possess in order to perform these procedures and
how vascular societies should monitor these competencies
and the procedural outcomes to provide credentialing for
performing such procedures.
A minimum number of EVAR with devices of the FBSG
lineage seems obvious and mandatory. The most important
parts of a FEVAR case are the pre-operative planning and
intra-operative troubleshooting when unexpected chal-
lenges are encountered during the procedure. This is where
the learning curve is steepest. Most experienced inter-
ventionalists can navigate a wire and catheter through
a fenestration into an artery, but what gets most into
trouble is poor pre-operative planning and not having the
knowledge and experience of troubleshooting when things
do not go as planned. Therefore, proper proctoring is
necessary until a requisite level of competency and comfort
are achieved in these two areas.
The FDA currently requires Cook Medical to provide
a detailed training program for physicians who will have
access to FBSG, including an extensive educational process
as well the presence of a proctor in the ﬁrst 5 cases per-
formed by a new operator. It is important to emphasize that
it is not the absolute number of cases that should be used
as criteria to assess competency, but the level of comfort
one develops with the steps of the procedure as well as the
planning and troubleshooting aspect. This needs to be
individualized and may be as little as 1e2 cases for some
and as high as 15e20 cases or more for others.
Surgeons who are trained in the technique of open repair
of complex aneurysms and with adequate endovascular
skills, who meet these “requirements”, should be afforded
the opportunity to treat complex aneurysms with FEVAR.WHAT HAVE WE LEARNED FROM CENTRALIZATION OF
FEVAR SO FAR?
The FBSG device from Cook Medical has been commercially
available in Europe for many years. The slow process of the
FDA approval in the United States however, mainly because
of the lack of a FEVAR-dedicated renal artery stent in the
U.S. trial, led to a signiﬁcant delay in commercialization.
Thus, a centralization of FEVAR in the U.S. for the last
decade was inevitable. The most positive aspect of this
centralization was that vast experience has been collected
with FEVAR in the handful of trial-participating centers that
were pioneering this technological advance, while creating
the foundation for expertise and innovation.
On the other hand, the need for FBSG was so apparent to
treat patients unﬁt for open repair or conventional EVAR
that the demand in the few institutions providing therapy
with FEVAR became large and patients with complex
aneurysms were put on waiting lists that were often
longer than the time needed to custom manufacture thegrafts. With the annual risk of rupture estimated at 9.4% for
a 5.5e5.9 cm AAA, 10.2% for AAA of 6.0e6.9 cm, and 32.5%
for AAA of 7.0 cm or more, it is obvious that this not
a benign waiting time, and it isn’t uncommon for patients to
rupture their aneurysms while waiting for their turn on the
list.20 By centralizing and restricting access to this tech-
nology we have done a disservice to our patients.
In addition, the lack of availability and proper training on
FEVAR has led many physicians to adopt other techniques
out of necessity in order to provide treatment to their
patients.We have chosen to manufacture our own surgeon-
modiﬁed FBSG21,22 currently within an FDA approved
Investigational Device Exemption (IDE). However others
have chosen to adopt off-label, non-FDA approved tech-
niques with uncertain durability such as the Chimneye
SnorkeleSandwich techniques exposing patients to unnec-
essary risks and potentially suboptimal results.23e25 Some
have gone even more to the extreme in order to treat
thoracoabdominal aneurysms with off-the-shelf devices of
currently available grafts with adventurous techniques that
include up to 20 separate pieces, which has been heavily
criticized by propagators of FEVAR.26,27
The discussion about centralization is therefore self-
limiting if by restricting access to FEVAR technology, we are
encouraging surgeons across the globe to use techniques
that put patients at unnecessary increased risk, compromise
durability of repair and are far from optimal.WHAT IS THE CURRENT STATUS OF FEVAR?
FEVAR technology is continuously evolving, thanks to the
excellent work of FEVAR enthusiasts such as our co-debater
Dr. Haulon. The recent development of off-the-shelf fenes-
trated devices for juxtarenal aneurysms with pre-loaded
fenestrations eliminates time-consuming steps that add to
the complexity of FEVAR, such as branch cannulation in
addition to eliminating the requisite time required to
custom manufacture a device.9,28,29 This signiﬁcantly
contributes to an easier use of FBSG by more vascular
surgeons.
More and more data on FEVAR accumulates daily, sug-
gesting that FEVAR can be performed safely by surgeons
who perform even limited number of these procedures.
Recently, collaborators of the GLOBALSTAR database pub-
lished their experience from 14 centers in the UK, which
had performed >10 FEVAR procedures for juxta- and par-
arenal aneurysms.16 They reported a 99% procedural
success rate with 0.6% of branches unable to be cannulated
intra-operatively. The overall perioperative mortality was
4.1%, while mortality was 2.7% in patients with renal
fenestrations alone, 2.9% in patients with renal fenestra-
tions and a fenestration/scallop to the SMA, and 9.4% for
patients requiring incorporation of the celiac trunk in their
FBSG. This current publication is probably the best example
of how one can achieve excellent results with juxtarenal
FEVAR even with limited experience, as long as the requisite
endovascular skills and comfort level with the procedure
are present. According to the suggestions of Greenberg
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be performed according to the extent of the repair
required, so that aneurysms requiring 4 fenestrations would
fall into the type IV TAAA repair category.30 The UK paper
which demonstrated that mortality increases as the extent
of the repair becomes more complex supports our argu-
ment that a 3e4 fenestrations-FEVAR represents a different
challenge than a 1e2 fenestrations-FEVAR, with or without
scallop to the SMA.
We recently reported real-world data for FEVAR using the
American College of Surgeons National Surgical Quality
Improvement Program (ACS-NSQIP), which collects data
from more than 300 institutions across the United States.31
In 264 FEVAR patients randomly captured from these
institutions, the 30-day mortality was 0.8%, risk of any
complication was18% and the risk of any renal complication
was1.5%. Although these data are limited by the lack of
information concerning the extent of repair, they reﬂect the
excellent results achieved with FEVAR on a national scale
which includes data from several centers across the U.S.
that perform both FBSG in the setting of a clinical trial as
well as data from sites performing surgeon-modiﬁed FBSG.
WHAT THE FUTURE IN FEVAR SHOULD LOOK LIKE?
As much as Dr. Haulon tries to convince us that FBSG should
be restricted to a few centers, he is in this debate a victim
of his own work on off-the-shelf devices which signiﬁcantly
reduce the complexity of FEVAR and make it possible for
every surgeon with endovascular skills and an under-
standing of FEVAR principles to perform these procedures.
For vascular surgery to evolve and remain ahead of the
technological advancements, any new technology should be
disseminated as widely as possible in a controlled fashion
that allows close monitoring of outcomes. Only in this way
will we be able to attract industry interest in these tech-
niques and further develop available devices. Proper
training and proctoring should be promoted and considered
a prerequisite by industry and vascular societies.
The goal of the vascular societies across the world should
be to properly train physicians during their formal training
and afterward to be able to use FBSG to perform a 2-vessel
FEVAR (þ/ SMA scallop) in any vascular unit with a sufﬁ-
cient aortic workload.
We do not need only a few centers of excellence and few
“all-star vascular surgeons”, but rather a strong widespread
vascular community with access to the latest devices and
technology who possess the requisite skills and comfort
level to safely and effectively treat the many patients who
can beneﬁt from this technology in as many places across
the world as possible.
CONCLUSION
All vascular surgeons trained in open aortic surgery should
be able to treat open pararenal aneurysms in the elective
and emergent setting and the same should apply for FEVAR.
The use of FEVAR for patients with juxta, pararenal aneu-
rysms with 1e2 fenestrations and an SMA scallop shouldbelong in the armamentarium of all vascular surgeons who
treat aortic aneurysms. By restricting access to this tech-
nology and not properly training our vascular surgery
community, we are doing a disservice to our patients by
restricting their access to the therapy as well and subjecting
them to unproven and potentially unsafe procedures.
REFERENCES
1 Ehsan O, Murray D, Farquharson F, Serracino-Inglott F. Endo-
vascular repair of complex aortic aneurysms. Ann Vasc Surg
2011;25(5):716e25.
2 Greenberg RK, Sternbergh 3rd WC, Makaroun M, Ohki T,
Chuter T, Bharadwaj P, et al. Intermediate results of a United
States multicenter trial of fenestrated endograft repair for
juxtarenal abdominal aortic aneurysms. J Vasc Surg 2009;50(4):
730 e1e7 e1.
3 Verhoeven EL, Tielliu IF, Muhs BE, Bos WT, Zeebregts CJ,
Prins TR, et al. Fenestrated and branched stent-grafting:
a 5-years experience. Acta Chir Belg 2006;106(3):317e22.
4 Anderson JL, Berce M, Hartley DE. Endoluminal aortic grafting
with renal and superior mesenteric artery incorporation by
graft fenestration. J Endovasc Ther 2001;8(1):3e15.
5 Park JH, Chung JW, Choo IW, Kim SJ, Lee JY, Han MC. Fenes-
trated stent-grafts for preserving visceral arterial branches in
the treatment of abdominal aortic aneurysms: preliminary
experience. J Vasc Interv Radiol 1996;7(6):819e23.
6 Semmens JB, Lawrence-Brown MM, Hartley DE, Allen YB,
Green R, Nadkarni S. Outcomes of fenestrated endografts in
the treatment of abdominal aortic aneurysm in Western
Australia (1997e2004). J Endovasc Ther 2006;13(3):320e9.
7 Troisi N, Donas KP, Austermann M, Tessarek J, Umscheid T,
Torsello G. Secondary procedures after aortic aneurysm repair
with fenestrated and branched endografts. J Endovasc Ther
2011;18(2):146e53.
8 Mastracci TM, Greenberg RK, Eagleton MJ. SS6. Long-term
durability of branched and fenestrated endografts. J Vasc Surg
2012;55(Suppl. 6):19S.
9 Clair D, Holden A, Hill A, Mertens R, Marine L. Initial pilot study
outcomes of the Ventana fenestrated stent graft system for
endovascular repair of juxtarenal and pararenal aortic aneu-
rysms. Las Vegas: SCVS; 2012.
10 Bungay PM, Burﬁtt N, Sritharan K, Muir L, Khan SL, De
Nunzio MC, et al. Initial experience with a new fenestrated
stent graft. J Vasc Surg 2011;54(6):1832e8.
11 Tsilimparis N, Ricotta II JJ. Type IV thoracoabdominal aneu-
rysms: what’s next? J Endovasc Today 2012 March:56e63.
12 Tsai S, Conrad MF, Patel VI, Kwolek CJ, Lamuraglia GM,
Brewster DC, et al. Long-term durability of open repair of
juxtarenal abdominal aortic aneurysms. J Vasc Surg 2012;56(1):
2e7.
13 Jongkind V, Yeung KK, Akkersdijk GJ, Heidsieck D, Reitsma JB,
Tangelder GJ, et al. Juxtarenal aortic aneurysm repair. J Vasc
Surg 2010;52(3):760e7.
14 PiazzaM, Ricotta 2nd JJ. Open surgical repair of thoracoabdominal
aortic aneurysms. Ann Vasc Surg 2011;26(4):600e5.
15 Conrad MF, Crawford RS, Davison JK, Cambria RP. Thor-
acoabdominal aneurysm repair: a 20-year perspective. Ann
Thorac Surg 2007;83(2):S856e61 [discussion S90e2].
16 On behalf of the British Society for Endovascular Therapy and
the Global Collaborators. Early results of fenestrated endo-
vascular repair of juxtarenal aortic aneurysms in the United
Kingdom. Circulation 2012;125(22):2707e15.
N. Tsilimparis and J.J. Ricotta II 20717 Verhoeven E, Tielliu IF, Zeebregts CJ, Bekkema F, Vourliotakis G,
Ritter W, et al. Results of endovascular repair of TAAA in the
ﬁrst 50 patients. Zentralbl Chir 2011;136(5):451e7.
18 Guillou M, Bianchini A, Sobocinski J, Maurel B, D’Elia P,
Tyrrell M, et al. Endovascular treatment of thoracoabdominal
aortic aneurysms. J Vasc Surg 2012;56(1):65e73.
19 Young EL, Holt PJ, Poloniecki JD, Loftus IM, Thompson MM. Met-
aanalysis and systematic review of the relationship between
surgeon annual caseload and mortality for elective open abdom-
inal aortic aneurysm repairs. J Vasc Surg 2007;46(6):1287e94.
20 Lederle FA, Johnson GR, Wilson SE, Ballard DJ, Jordan Jr WD,
Blebea J, et al. Rupture rate of large abdominal aortic aneu-
rysms in patients refusing or unﬁt for elective repair. J Am Med
Assoc 2002;287(22):2968e72.
21 Ricotta 2nd JJ, Oderich GS. Fenestrated and branched stent
grafts. Perspect Vasc Surg Endovasc Ther 2008;20(2):174e87
[discussion 88e9].
22 Ricotta II JJ, Tsilimparis N. Outcomes of surgeon-modiﬁed
fenestrated-branched stent-grafts to emergently treat ruptured
and symptomatic complex aortic aneurysms in high risk-
patients. J Vasc Surg 2012;56(6):1535e42.
23 Moulakakis KG, Mylonas SN, Avgerinos E, Papapetrou A,
Kakisis JD, Brountzos EN, et al. The chimney graft technique for
preserving visceral vessels during endovascular treatment of
aortic pathologies. J Vasc Surg 2012;55(5):1497e503.
24 Bruen KJ, Feezor RJ, Daniels MJ, Beck AW, Lee WA. Endovas-
cular chimney technique versus open repair of juxtarenal andsuprarenal aneurysms. J Vasc Surg 2011;53(4):895e904
[discussion 904e5].
25 Lachat M, Pecoraro F, Pfammatter T, Frauenfelder T, Glenck M,
Bettex D, et al. SS8. Chimney and periscope grafts: mid-term
results in 77 consecutive patients with complex aortic aneu-
rysms. J Vasc Surg 2012;55(Suppl. 6):20S.
26 Kasirajan K. Branched grafts for thoracoabdominal aneurysms:
off-label use of FDA-approved devices. J Endovasc Ther
2011;18(4):471e6.
27 Chuter TAM, Greenberg RK. Re: “Branched grafts for thor-
acoabdominal aneurysms: off-label use of FDA-approved
devices” by Dr. Karthik Kasirajan. J Endovasc Ther 2011;18(6):
820e2.
28 Sobocinski J, d’Utra G, O’Brien N, Midulla M, Maurel B,
Guillou M, et al. Off-the-shelf fenestrated endografts: a realistic
option for more than 70% of patients with juxtarenal aneu-
rysms. J Endovasc Ther 2012;19(2):165e72.
29 Resch TA, Dias NV, Sobocinski J, Sonesson B, Roeder B, Haulon S.
Development of off-the-shelf stent grafts for juxtarenal
abdominal aortic aneurysms. Eur J Vasc Endovasc Surg
2012;43(6):655e60.
30 Greenberg RK, Lytle B. Endovascular repair of thor-
acoabdominal aneurysms. Circulation 2008;117(17):2288e96.
31 Tsilimparis N, Perez S, Dayama A, Ricotta II JJ. Endovascular
repair with fenestrated-branched stent grafts improves 30-day
outcomes for complex aortic aneurysms compared to open
repair. Ann Vasc Surg, in press.
